Covid Cure Breaking News: Roche/Regeneron Antibody Cocktail Approved!

Covid Cure Breaking News: Roche/Regeneron Antibody Cocktail Approved!
SHARE

Amidst tons and tons of news about the coronavirus vaccines, some firms are also working really hard in order to find potentially viable treatments for the disease produced by the novel coronavirus.

For instance, not too long ago, we addressed Pfizer’s experimental oral drug that treats Covid-19 at the very first sign will be available by the end of this year, the company’s CEO said.

On the other hand, Pfizer has been making headlines lately due to some issues that have been popping up around their vaccine.

Now, news about other viable treatments is popping up!

Covid treatment breakthrough 

According to the latest reports coming from Reuters, India has given emergency use authorization for a COVID-19 antibody-drug cocktail developed by Roche (ROG.S) and Regeneron (REGN.O) –  this way, the country expanded its arsenal of drugs to battle a massive second wave of infections.

It’s been also revealed that this decision has been taken based on data filed with the U.S. regulators and the scientific opinion of a European regulatory panel, Roche’s India distribution partner for the drug, Cipla (CIPL.NS), said on Wednesday.

It’s important to note the fact that this therapy is a cocktail of two antibodies, Casirivimab and Imdevimab – these are synthetically manufactured copies of antibodies that the body produces after an infection.

“It has been shown to reduce hospitalizations in COVID-19 patients who are at a high risk of developing severe illness,” Reuters notes.

The news agency also pointed out the fact that the drug already has similar authorization in the United States and is used in Europe non-hospitalised patients.

We suggest that you check out the complete notes that Reuters posted on their article in order to learn all the available details on the matter. 

Other than this, vaccines are being shipped all over the world, and experts are weighing in on the benefits vs. the risks. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.